Search Result

Results for "

bowel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (11) Adenosine Receptor (2) Adrenergic Receptor (2) Akt (1) Aminopeptidase (1) Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (10) Aurora Kinase (3) Bacterial (5) Calcium Channel (2) CCR (5) CDK (1) COX (1) CRFR (1) CX3CR1 (1) CXCR (3) Dihydroorotate Dehydrogenase (3) Dopamine Transporter (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) Epigenetic Reader Domain (1) ERK (1) FXR (2) GCGR (3) GLP Receptor (2) GPR68 (1) Guanylate Cyclase (3) HIF/HIF Prolyl-Hydroxylase (2) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Integrin (2) Interleukin Related (6) Isotope-Labeled Compounds (3) JAK (6) Leukotriene Receptor (2) mAChR (7) Motilin Receptor (1) Neurokinin Receptor (1) NF-κB (3) NO Synthase (2) NOD-like Receptor (NLR) (2) Oct3/4 (1) Opioid Receptor (3) Parasite (3) Phosphodiesterase (PDE) (3) PIKfyve (1) Potassium Channel (3) Prostaglandin Receptor (1) RET (2) RIP kinase (4) ROR (2) Sodium Channel (2) STAT (1) STING (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) TRP Channel (1) Virus Protease (3)
By Research Areas:	Cancer (16) Cardiovascular Disease (2) Endocrinology (5) Infection (7) Inflammation/Immunology (77) Metabolic Disease (33) Neurological Disease (21)

By Targets:

5-HT Receptor (11)

Adenosine Receptor (2)

Adrenergic Receptor (2)

Akt (1)

Aminopeptidase (1)

Antibiotic (2)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (10)

Aurora Kinase (3)

Bacterial (5)

Calcium Channel (2)

CCR (5)

CDK (1)

COX (1)

CRFR (1)

CX3CR1 (1)

CXCR (3)

Dihydroorotate Dehydrogenase (3)

Dopamine Transporter (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (4)

Epigenetic Reader Domain (1)

ERK (1)

FXR (2)

GCGR (3)

GLP Receptor (2)

GPR68 (1)

Guanylate Cyclase (3)

HIF/HIF Prolyl-Hydroxylase (2)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (3)

Integrin (2)

Interleukin Related (6)

Isotope-Labeled Compounds (3)

JAK (6)

Leukotriene Receptor (2)

mAChR (7)

Motilin Receptor (1)

Neurokinin Receptor (1)

NF-κB (3)

NO Synthase (2)

NOD-like Receptor (NLR) (2)

Oct3/4 (1)

Opioid Receptor (3)

Parasite (3)

Phosphodiesterase (PDE) (3)

PIKfyve (1)

Potassium Channel (3)

Prostaglandin Receptor (1)

RET (2)

RIP kinase (4)

ROR (2)

Sodium Channel (2)

STAT (1)

STING (1)

TNF Receptor (4)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

Virus Protease (3)

By Research Areas:

Cancer (16)

Cardiovascular Disease (2)

Endocrinology (5)

Infection (7)

Inflammation/Immunology (77)

Metabolic Disease (33)

Neurological Disease (21)

121

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137789

Tazofelone LY 213829	COX	Cancer
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .

HY-148531

PF-07054894	CCR	Inflammation/Immunology
PF-07054894 is a potent CCR6 antagonist. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease .

HY-107649

Zamifenacin fumarate UK-76654 fumarate	mAChR	Metabolic Disease
Zamifenacin fumarate (UK-76654 fumarate) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-115744

Mercaptoethylguanidine (MEG) (dihydrobromide)	NO Synthase	Inflammation/Immunology
Mercaptoethylguanidine (MEG) dihydrobromide is selective inhibitor of the inducible nitric oxide synthase and peroxynitrite scavenger. Mercaptoethylguanidine (MEG) dihydrobromide has the potential for inflammatory bowel diseases research.

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-123337

Zamifenacin UK-76654	mAChR	Metabolic Disease
Zamifenacin (UK-76654) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-111613

Pinaverium bromide 3 Publications Verification	Calcium Channel	Cancer
Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-118795

SC-22716	Aminopeptidase	Inflammation/Immunology
SC-22716 is a potent, competitive, reversible inhibitor of human LTA₄ hydrolase, with an IC₅₀ of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .

HY-147527

CDK8-IN-5	CDK	Inflammation/Immunology
CDK8-IN-5 is a potent CDK8 inhibitor with an IC₅₀ of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease .

HY-151952

NLRP3-IN-12	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC₅₀ of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease .

HY-B0499A

Otilonium bromide 2 Publications Verification Octylonium bromide; SP63	mAChR	Neurological Disease
Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-P3291

Dapiglutide ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research .

HY-19667A

BMS-561392 formate DPC 333 formate	TNF Receptor	Inflammation/Immunology
BMS-561392 formate is the formate form of BMS-561392 (HY-19667). BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .

HY-15707

NS6180	Potassium Channel	Inflammation/Immunology
NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC₅₀value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .

HY-P1142

GLP-2(rat)	Apoptosis	Others
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-P1142A

GLP-2(rat) TFA	Apoptosis	Others
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-12820

Sibofimloc 1 Publications Verification Antibiotic-202	Bacterial Antibiotic	Infection
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-18263

Elubrixin hydrochloride SB-656933 hydrochloride	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-100459

GSK3179106 3 Publications Verification	RET	Metabolic Disease Inflammation/Immunology
GSK3179106 is an orally active and selective RET kinase inhibitor with IC₅₀s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-14147A

(S)-Renzapride (S)-BRL 24924	5-HT Receptor	Metabolic Disease
(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-155680

BET BD2-IN-1	Epigenetic Reader Domain	Inflammation/Immunology
BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC₅₀=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-107384

Asimadoline EMD-61753	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-107384A

Asimadoline hydrochloride EMD-61753 hydrochloride	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) (TFA)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-155199

PDE1-IN-5	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC₅₀: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .

HY-44809

Izilendustat	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Inflammation/Immunology
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .

HY-111191

ONO-2952	Adrenergic Receptor	Neurological Disease
ONO-2952 is a potent, selective and orally active translocator protein 18 kDa (TSPO) antagonist with K_i of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment .

HY-106982

Ezlopitant CJ-11,974	Neurokinin Receptor	Neurological Disease Metabolic Disease
Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .

HY-P9984

Etrolizumab rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-14908

Vidofludimus 1 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-136233

PSB 0777 ammonium	Adenosine Receptor	Inflammation/Immunology
PSB 0777 ammonium is a potent and selective adenosine A_2A receptor full agonist with K_i values of 44.4 nM, 360 nM for rat and human A_2A receptors, respectively. PSB 0777 ammonium has K_i values of ≥10000 nM, 541 nM for rat and human A₁ receptors, respectively. PSB 0777 ammonium shows poor brain penetrant and perorally non-absorbable effect. PSB 0777 ammonium has the potential for inflammatory bowel disease (IBS) research research .

HY-136233A

PSB 0777 ammonium hydrate	Adenosine Receptor	Inflammation/Immunology
PSB 0777 ammonium hydrate is a potent and selective adenosine A_2A receptor full agonist with K_i values of 44.4 nM, 360 nM for rat and human A_2A receptors, respectively. PSB 0777 ammonium hydrate has K_i values of ≥10000 nM, 541 nM for rat and human A₁ receptors, respectively. PSB 0777 ammonium hydrate shows poor brain penetrant and perorally non-absorbable effect. PSB 0777 ammonium hydrate has the potential for inflammatory bowel disease (IBS) research research .

HY-109182

Lorpucitinib

JNJ-64251330
JAK Inflammation/Immunology

Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease .

Lorpucitinib JNJ-64251330	JAK	Inflammation/Immunology
Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease .

HY-115497

BRD5529	E1/E2/E3 Enzyme	Infection Inflammation/Immunology
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC₅₀ value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .

HY-B0174

Olsalazine Disodium	Leukotriene Receptor Antibiotic	Inflammation/Immunology
Olsalazine Disodium is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .

Cat. No.	Product Name

HY-L078

Gut Microbial Metabolite Library

500 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 500 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L103

Anti-Colorectal Cancer Compound Library

1618 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1618 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L014

NF-κB Signaling Compound Library

805 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 805 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P3291

Dapiglutide ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research .

HY-P1142

GLP-2(rat)	Apoptosis	Others
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-P1142A

GLP-2(rat) TFA	Apoptosis	Others
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) (TFA)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-17584

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P3282

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P1714

Apraglutide FE 203799	GLP Receptor	Metabolic Disease
Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-105174

BPC 157	Endogenous Metabolite	Inflammation/Immunology
BPC 157 is a stable gastric pentadecapeptide and a partial sequence of the human gastric juice protein BPC. BPC 157 is an anti-ulcer peptidergic agent with no reported toxicity. BPC 157 links inflammatory bowel disease and multiple sclerosis .

HY-P1714A

Apraglutide TFA FE 203799 TFA	GLP Receptor	Metabolic Disease
Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-P1624

Teduglutide ALX-0600	Peptides	Inflammation/Immunology
Teduglutide is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide is associated with trophic effects on gut mucosa. Teduglutide can be used for the research of short bowel syndrome (SBS) and Crohn's disease (CD) .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Peptides	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA is associated with trophic effects on gut mucosa. Teduglutide TFA can be used for the research of short bowel syndrome (SBS) and Crohn's disease (CD) .

HY-P10081

CTP-NBD

NF-κB Inflammation/Immunology

CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-105174

BPC 157	Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite
BPC 157 is a stable gastric pentadecapeptide and a partial sequence of the human gastric juice protein BPC. BPC 157 is an anti-ulcer peptidergic agent with no reported toxicity. BPC 157 links inflammatory bowel disease and multiple sclerosis .

HY-B2134

Casanthranol	Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Others
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N0110

Palmatine chloride 5 Publications Verification	Alkaloids Structural Classification Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N0110B

Palmatine hydroxide 5 Publications Verification	Alkaloids Phellodendron amurense Rupr. Source classification Rutaceae Plants	Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0110R

Palmatine chloride (Standard)	Structural Classification Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Plants Disease Research Fields Cancer	Apoptosis Virus Protease Indoleamine 2,3-Dioxygenase (IDO) Parasite Bacterial Aurora Kinase
Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

Cat. No.	Product Name	Chemical Structure

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1[1][2].

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) (TFA)
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-111613S

Pinaverium bromide-d4
Pinaverium bromide-d₄ is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

bowel

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products